

APPENDIX 19: CLINICAL EVIDENCE – FOREST PLOTS

1.1	Case identification	13
1.1.1	Depression: EPDS – Sensitivity and Specificity	13
1.1.2	Depression: PHQ – Sensitivity and Specificity.....	17
1.1.3	Depression – Whooley Questions: Sensitivity and Specificity.....	18
1.1.4	Depression: Kessler-10 – Sensitivity and Specificity	18
1.1.5	Anxiety: EPDS – Sensitivity and Specificity	19
1.1.6	Anxiety: Kessler-10 – Sensitivity and Specificity	20
1.2	Psychosocial interventions: Prevention (risk factors identified).....	20
1.2.1	Depression: Post-miscarriage self-help versus TAU	20
1.2.2	Depression: Social support versus TAU.....	20
1.2.3	Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU.....	21
1.2.4	Depression: Psychoeducational booklet versus TAU or Enhanced TAU	23
1.2.5	Depression: Non-mental health-focused education and support versus TAU or Enhanced TAU.....	25
1.2.6	Depression: Home visits versus TAU.....	28
1.2.7	Depression: Post-delivery discussion versus Enhanced TAU	30
1.2.8	Depression: Mother-infant relationship interventions versus TAU	32
1.2.9	Depression: Case management and individualised treatment versus TAU...	34
1.2.10	Anxiety: Post-miscarriage self-help versus TAU	35
1.2.11	Anxiety: Non-mental health-focused education and support versus TAU or Enhanced TAU	35
1.2.12	Anxiety: Home visits versus TAU.....	37
1.2.13	PTSD: Post-miscarriage self-help versus TAU	39
1.2.14	General mental health: Post-miscarriage self-help versus TAU.....	39
1.2.15	General mental health: Home visits versus TAU	40
1.2.16	General mental health: Post-delivery discussion versus Enhanced TAU	40
1.2.17	General mental health: Mother-infant relationship interventions versus TAU	40
1.2.18	Mother-infant attachment: Non-mental health-focused education and support versus TAU or Enhanced TAU	41
1.2.19	Mother-infant attachment: Home visits versus TAU	43

1.2.20	Mother-infant attachment: Mother-infant relationship interventions versus TAU	44
1.2.21	Mother-infant attachment: Case management and individualised treatment versus TAU	48
1.2.22	Quality of life: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU	48
1.2.23	Quality of life: Non-mental health-focused education and support versus TAU or Enhanced TAU	49
1.2.24	Quality of life: Home visits versus TAU	50
1.2.25	Quality of life: Mother-infant relationship interventions versus TAU	50
1.2.26	Quality of life: Case management and individualised treatment versus TAU	51
1.2.27	Service utilisation: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU	52
1.2.28	Service utilisation: Home visits versus TAU	52
1.2.29	Experience of care: Non-mental health-focused education and support versus TAU or Enhanced TAU	53
1.2.30	Attrition: Post-miscarriage self-help versus TAU	54
1.2.31	Attrition: Social support versus TAU	54
1.2.32	Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU	54
1.2.33	Attrition: Psychoeducational booklet versus TAU or Enhanced TAU	55
1.2.34	Attrition: Non-mental health-focused education and support versus TAU or Enhanced TAU	55
1.2.35	Attrition: Home visits versus TAU	55
1.2.36	Attrition: Post-delivery discussion versus Enhanced TAU	56
1.2.37	Attrition: Mother-infant relationship interventions versus TAU	56
1.2.38	Infant physical health: Home visits versus TAU	56
1.2.39	Infant regulatory problems: Mother-infant relationship interventions versus TAU	57
1.2.40	Infant physical development: Home visits versus TAU	59
1.2.41	Infant cognitive development: Home visits versus TAU	60
1.2.42	Infant emotional development: Home visits versus TAU	65
1.2.43	Infant emotional development: Mother-infant relationship interventions versus TAU	71
1.2.44	Prevention of neglect or abuse of the infant: Home visits versus TAU	71

1.3	Protocols for women following stillbirth	73
1.3.1	Mental health outcomes for women who saw versus did not see their stillborn infant	73
1.3.2	Mental health outcomes for women who held versus did not hold their stillborn infant	76
1.3.3	Mental health outcomes for women who spent as much time with stillborn infant as they wished versus those who did not	79
1.3.4	Mental health outcomes for women who kept a photo of their stillborn infant versus those who did not.....	79
1.3.5	Mental health outcomes for women who kept a token of remembrance of their stillborn infant versus those who did not	80
1.3.6	Mental health outcomes for women who took drug to stop milk production following stillbirth versus those who did not.....	80
1.4	Psychosocial interventions: Prevention (no risk factors identified)	80
1.4.1	Depression: Structured psychological interventions (CBT or IPT) versus TAU	80
1.4.2	Depression: Listening visits versus TAU	81
1.4.3	Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU	82
1.4.4	Depression: Home visits versus TAU.....	83
1.4.5	Depression: Post-delivery discussion versus TAU.....	84
1.4.6	Depression: Mother-infant relationship interventions versus Enhanced TAU.. ..	84
1.4.7	Depression: Mindfulness training versus TAU.....	85
1.4.8	Anxiety: Structured psychological interventions (CBT or IPT) versus TAU..	85
1.4.9	Anxiety: Listening visits versus TAU	85
1.4.10	Anxiety: Post-delivery discussion versus TAU.....	86
1.4.11	Anxiety: Music therapy versus TAU	86
1.4.12	Anxiety: Mindfulness training versus TAU	86
1.4.13	General mental health: Structured psychological interventions (CBT or IPT) versus TAU	87
1.4.14	General mental health: Listening visits versus TAU	87
1.4.15	General mental health: Home visits versus TAU	88
1.4.16	General mental health: Mindfulness training versus TAU	88
1.4.17	Mother-infant attachment: Home visits versus TAU	89

1.4.18	Mother-infant attachment: Mother-infant relationship interventions versus Enhanced TAU	89
1.4.19	Mother-infant attachment: Mindfulness training versus TAU	91
1.4.20	Quality of life: Structured psychological interventions (CBT or IPT) versus TAU	91
1.4.21	Quality of life: Listening visits versus TAU.....	92
1.4.22	Quality of life: Home visits versus TAU	93
1.4.23	Quality of life: Mother-infant relationship interventions versus Enhanced TAU	93
1.4.24	Quality of life: Music therapy versus TAU	94
1.4.25	Quality of life: Mindfulness training versus TAU	94
1.4.26	Attrition: Structured psychological interventions (CBT or IPT) versus TAU.	94
1.4.27	Attrition: Listening visits versus TAU.....	94
1.4.28	Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus Enhanced TAU	95
1.4.29	Attrition: Home visits versus TAU	95
1.4.30	Attrition: Mindfulness training versus TAU	95
1.5	Psychosocial interventions: Treatment	96
1.5.1	Depression: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU	96
1.5.2	Depression: CBT versus listening visits	102
1.5.3	Depression: CBT versus Relational Constructivist Therapy	102
1.5.4	Depression: IPT versus support group.....	102
1.5.5	Depression: Facilitated self-help versus TAU	103
1.5.6	Depression: Post-miscarriage self-help versus TAU	103
1.5.7	Depression: Post-miscarriage facilitated self-help versus TAU.....	104
1.5.8	Depression: Directive counselling versus TAU	105
1.5.9	Depression: Listening visits versus TAU	106
1.5.10	Depression: Post-miscarriage counselling versus TAU	110
1.5.11	Depression: Post-traumatic birth counselling versus TAU	111
1.5.12	Depression: Social support versus TAU.....	112
1.5.13	Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	114
1.5.14	Depression: IPT-informed psychoeducation versus non-mental health-focused education and support	118

1.5.15	Depression: Non-mental health-focused education and support versus TAU ..	119
1.5.16	Depression: Home visits versus TAU/Enhanced TAU	119
1.5.17	Depression: Mother-infant relationship interventions versus TAU/Enhanced TAU	121
1.5.18	Depression: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback	125
1.5.19	Depression: Co-parenting intervention versus Enhanced TAU	125
1.5.20	Depression: Infant sleep training (controlled crying) versus TAU/Enhanced TAU	126
1.5.21	Depression: Music therapy during birth versus TAU	127
1.5.22	Depression: Psychosomatic intervention versus TAU	128
1.5.23	Depression: Mindfulness training versus Enhanced TAU	128
1.5.24	Anxiety: Structured psychological interventions versus TAU/Enhanced TAU	129
1.5.25	Anxiety: CBT versus Relational Constructivist Therapy	130
1.5.26	Anxiety: IPT versus support group	130
1.5.27	Anxiety: Facilitated self-help versus TAU	130
1.5.28	Anxiety: Post-miscarriage self-help versus TAU	131
1.5.29	Anxiety: Listening visits versus TAU	132
1.5.30	Anxiety: Directive counselling versus TAU	132
1.5.31	Anxiety: Post-miscarriage counselling versus Enhanced TAU	132
1.5.32	Anxiety: Post-traumatic birth counselling versus TAU	133
1.5.33	Anxiety: Social support versus TAU	133
1.5.34	Anxiety: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	134
1.5.35	Anxiety: Mother-infant relationship interventions versus TAU/Enhanced TAU	135
1.5.36	Anxiety: Music therapy during birth versus TAU	136
1.5.37	Anxiety: Psychosomatic intervention versus TAU	136
1.5.38	Anxiety: Mindfulness training versus Enhanced TAU	137
1.5.39	Adjustment disorder: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	137
1.5.40	PTSD: Post-miscarriage self-help versus TAU	138
1.5.41	PTSD: Post-traumatic birth counselling versus TAU	138

1.5.42	PTSD: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	139
1.5.43	PTSD: Mother-infant relationship interventions versus TAU/Enhanced TAU.	140
1.5.44	OCD: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	142
1.5.45	Fear of childbirth: Pre-delivery discussion/psychoeducation versus TAU .	144
1.5.46	Eating disorder: Mother-infant relationship interventions (and guided self-help) versus listening visits (and guided self-help)	147
1.5.47	General mental health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU	147
1.5.48	General mental health: IPT versus support group	148
1.5.49	General mental health: Post-miscarriage self-help versus TAU	149
1.5.50	General mental health: Listening visits versus TAU	149
1.5.51	General mental health: Post-miscarriage counselling versus TAU	150
1.5.52	General mental health: Post-traumatic birth counselling versus TAU	150
1.5.53	General mental health: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	151
1.5.54	General mental health: Home visits versus TAU/Enhanced TAU	152
1.5.55	General mental health: Mother-infant relationship interventions versus TAU/Enhanced TAU	153
1.5.56	General mental health: Co-parenting intervention versus Enhanced TAU..	154
1.5.57	Mother-infant attachment: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU	154
1.5.58	Mother-infant attachment: Facilitated self-help versus TAU	157
1.5.59	Mother-infant attachment: Listening visits versus TAU	157
1.5.60	Mother-infant attachment: Social support versus TAU	159
1.5.61	Mother-infant attachment: Psychologically (CBT/IPT) – informed psychoeducation versus Enhanced TAU	160
1.5.62	Mother-infant attachment: Home visits versus TAU/Enhanced TAU	160
1.5.63	Mother-infant attachment: Mother-infant relationship interventions versus TAU/Enhanced TAU	161
1.5.64	Mother-infant attachment: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback ..	169

1.5.65	Mother-infant attachment: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help).....	170
1.5.66	Quality of life: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU	172
1.5.67	Quality of life: IPT versus support group	174
1.5.68	Quality of life: Facilitated self-help versus TAU.....	175
1.5.69	Quality of life: Listening visits versus TAU.....	176
1.5.70	Quality of life: Directive counselling versus TAU	177
1.5.71	Quality of life: Post-miscarriage counselling versus TAU.....	177
1.5.72	Quality of life: Post-traumatic birth counselling versus TAU.....	177
1.5.73	Quality of life: Social support versus TAU	178
1.5.74	Quality of life: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU.....	179
1.5.75	Quality of life: Home visits versus TAU/Enhanced TAU.....	183
1.5.76	Quality of life: Mother-infant relationship interventions versus TAU/Enhanced TAU	183
1.5.77	Quality of life: Psychosomatic intervention versus TAU	184
1.5.78	Quality of life: Mindfulness training versus TAU/Enhanced TAU	185
1.5.79	Service utilisation: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU.....	185
1.5.80	Service utilisation: Facilitated self-help versus TAU.....	188
1.5.81	Service utilisation: Listening visits versus TAU.....	193
1.5.82	Service utilisation: Social support versus TAU	195
1.5.83	Experience of care: Mother-infant relationship interventions versus TAU/Enhanced TAU	197
1.5.84	Attrition: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU	198
1.5.85	Attrition: CBT versus Relational Constructivist Therapy.....	198
1.5.86	Attrition: IPT versus support group	198
1.5.87	Attrition: Facilitated self-help versus TAU	199
1.5.88	Attrition: Listening visits versus TAU.....	199
1.5.89	Attrition: Directive counselling versus TAU	199
1.5.90	Attrition: Post-miscarriage counselling versus TAU/Enhanced TAU	200
1.5.91	Attrition: Post-traumatic birth counselling versus TAU.....	200
1.5.92	Attrition: Social support versus TAU	200

1.5.93	Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	201
1.5.94	Attrition: Non-mental health-focused education and support versus TAU.	201
1.5.95	Attrition: Home visits versus TAU	201
1.5.96	Attrition: Mother-infant relationship interventions versus TAU/Enhanced TAU	202
1.5.97	Attrition: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback.....	202
1.5.98	Attrition: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)	202
1.5.99	Attrition: Co-parenting intervention versus Enhanced TAU.....	203
1.5.100	Attrition: Music therapy during birth versus TAU.....	203
1.5.101	Attrition: Psychosomatic intervention versus TAU.....	203
1.5.102	Attrition: Mindfulness training versus Enhanced TAU	204
1.5.103	Infant service use: Facilitated self-help versus TAU.....	204
1.5.104	Infant service use: Listening visits versus TAU	205
1.5.105	Infant service use: Home visits versus TAU	210
1.5.106	Infant service use: Mother-infant relationship interventions versus TAU/Enhanced TAU	212
1.5.107	Infant physical health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU.....	215
1.5.108	Infant physical health: IPT versus support group.....	217
1.5.109	Infant physical health: Listening visits versus TAU	217
1.5.110	Infant physical health: Social support versus TAU	218
1.5.111	Infant physical health: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU	218
1.5.112	Infant physical health: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help).....	219
1.5.113	Infant physical development: CBT versus listening visits.....	219
1.5.114	Infant physical development: Listening visits versus TAU.....	219
1.5.115	Infant physical development: Home visits versus TAU	220
1.5.116	Infant physical development: Mother-infant relationship interventions versus TAU/Enhanced TAU.....	221
1.5.117	Infant physical development: Infant sleep training (controlled crying) versus TAU	222

1.5.118	Infant cognitive development: CBT versus listening visits	222
1.5.119	Infant cognitive development: Listening visits versus TAU	223
1.5.120	Infant cognitive development: Social support versus TAU.....	224
1.5.121	Infant cognitive development: Home visits versus TAU.....	224
1.5.122	Infant cognitive development: Mother-infant relationship interventions versus TAU/Enhanced TAU.....	225
1.5.123	Infant emotional development: Social support versus TAU	225
1.5.124	Infant emotional development: Home visits versus TAU	225
1.5.125	Infant emotional development: Mother-infant relationship interventions versus TAU/Enhanced TAU.....	227
1.5.126	Infant emotional development: Infant sleep training (controlled crying) versus TAU	229
1.5.127	Prevention of neglect or abuse of the infant: Listening visits versus TAU	230
1.5.128	Prevention of neglect or abuse of the infant: Home visits versus TAU	231
1.5.129	Optimal infant care: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU.....	233
1.6	Pharmacological interventions: prevention (no risk factors)	234
1.6.1	Depression: Omega-3 versus placebo	234
1.6.2	Depression: Selenium versus placebo	235
1.6.3	Depression: Calcium versus placebo	235
1.6.4	Compliance: Selenium versus placebo	236
1.6.5	Quality of life: Calcium versus placebo.....	236
1.6.6	Infant outcomes: Omega-3 versus placebo	237
1.6.7	Leaving the study early: Omega-3 versus placebo	238
1.6.8	Adverse events/ Service utilisation: Omega-3 versus placebo	238
1.7	Pharmacological interventions (risk factors)	239
1.7.1	Depression: Thyroxine versus placebo.....	239
1.7.2	Depression: Norethisterone versus placebo	240
1.7.3	Compliance: Thyroxine versus placebo	241
1.7.4	Mother-Infant interaction: Norethisterone versus placebo	241
1.7.5	Leaving the study early: Norethisterone versus placebo	242
1.7.6	Adverse events: Norethisterone versus placebo	242
1.8	Pharmacological interventions: prevention (prophylaxis)	244
1.8.1	Depression: SSRI (Sertraline) versus placebo	244

1.8.2	Depression: TCA (Nortriptyline) versus placebo	244
1.8.3	Adverse events: SSRI (Sertraline) versus placebo.....	245
1.8.4	Adverse events: TCA (Nortriptyline) versus placebo	245
1.8.5	Leaving the study early: SSRI (Sertraline) versus placebo	246
1.8.6	Leaving the study early: TCA (Nortriptyline) versus placebo	246
1.9	Pharmacological interventions: treatment	246
1.9.1	Non-Response: Omega-3 versus Placebo	246
1.9.2	Non-response to treatment: SSRIs (sertraline/paroxetine) versus placebo ..	248
1.9.3	Non-response to treatment: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions	249
1.9.4	Non-response to treatment: SSRIs versus TCA	250
1.9.5	Depression: SSRIs versus Placebo	251
1.9.6	Depression: SSRIs versus TCA	252
1.9.7	Depression: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions	252
1.9.8	Depression: Antidepressants versus general supportive care	253
1.9.9	Depression: Omega-3 versus Placebo	253
1.9.10	Depression: Hormones (transdermal oestrogen) versus placebo	254
1.9.11	General mental health: SSRIs versus TCA	254
1.9.12	General mental health: SSRIs combined with psychosocial interventions versus placebo combined with psychosocial interventions.....	255
1.9.13	General mental health: SSRIs compared with placebo	256
1.9.14	Service utilisation: SSRIs combined with psychosocial interventions compared with Placebo combined with psychosocial interventions	257
1.9.15	Service Utilisation: SSRIs compared with Placebo	257
1.9.16	Leaving the Study early: SSRIs combined with psychological interventions compared with Placebo combined with psychological interventions	257
1.9.17	Leaving the Study early: SSRIs compared with Placebo	258
1.9.18	Leaving the Study early: SSRIs compared with TCAs	258
1.9.19	Leaving the Study early: Hormones versus placebo	259
1.9.20	Leaving the Study early: Omega-3 versus Placebo.....	259
1.9.21	Adverse events: SSRI combined with psychosocial interventions compared with Placebo compared with psychosocial interventions.....	259
1.9.22	Adverse events: omega-3 versus placebo	260

1.9.23	Adverse events: SSRIs versus placebo.....	261
1.9.24	Compliance: SSRIs versus Placebo.....	262
1.10	Harms for associated with specific drugs	263
1.10.1	Antidepressants: Teratogenic harms	263
1.10.2	Antidepressants: Neonatal and obstetric complications	276
1.10.3	Antipsychotics: Teratogenic harms.....	279
1.10.4	Antipsychotics: Neonatal and Obstetric Complications	280
1.10.5	Antipsychotics: Neurodevelopmental outcomes.....	285
1.10.6	Anticonvulsants: Teratogenic harms	287
1.10.7	Anticonvulsants: Neonatal and Obstetric harms	291
1.10.8	Anticonvulsants: Neurodevelopmental outcomes	294
1.10.9	Lithium: Teratogenic harms.....	298
1.10.10	Benzodiazepines: Teratogenic harms.....	299
1.10.11	Benzodiazepines: Neonatal and Obstetric complications.....	302
1.10.12	Stimulants (methylphenidate): Teratogenic harms.....	304
1.11	Physical interventions: Prevention.....	305
1.11.1	Depression: Physical activity verses treatment as usual.....	305
1.11.2	Depression: Physical activity combined with psychoeducation verses psychoeducation alone.....	305
1.11.3	Acupuncture versus placebo.....	306
1.12	Physical interventions: Treatment.....	306
1.12.1	Response: Acupuncture versus massage	306
1.12.2	Response: Depression specific acupuncture versus non-specific acupuncture..	307
1.12.3	Response: Bright light therapy versus placebo	307
1.12.4	Depression: Physical activity versus treatment as usual	308
1.12.5	Depression: Physical activity versus mutual support.....	308
1.12.6	Depression: Acupuncture versus massage	309
1.12.7	Depression: Depression-specific acupuncture versus non-depression specific acupuncture	310
1.12.8	Depression: Electroacupuncture versus non-invasive sham acupuncture ...	311
1.12.9	Depression: Massage combined with support versus support.....	311
1.12.10	Depression: Massage versus support.....	312
1.12.11	Depression: Bright light therapy versus placebo	312


Clinical evidence – forest plots

1.12.12	Anxiety: Physical activity versus treatment as usual	313
1.12.13	Anxiety: Electroacupuncture versus non-invasive sham acupuncture	313
1.12.14	General mental health outcomes: Physical activity versus treatment as usual	313


1.1 CASE IDENTIFICATION

1.1.1 Depression: EPDS – Sensitivity and Specificity


EPDS-Pregnancy – Mixed depression – 9/10 cut-off




EPDS-Pregnancy-Mixed depression – 12/13 cut-off




EPDS-Pregnancy-Mixed depression – 14/15 cut-off




EPDS-Pregnancy – Major depression – 9/10 cut-off




EPDS-Pregnancy – Major depression – 12/13 cut-off




EPDS-Pregnancy – Major depression – 14/15 cut-off




EPDS-Postnatal – Mixed depression – 9/10 cut-off




EPDS-Postnatal-Mixed depression – 12/13 cut-off



EPDS-Postnatal-Major depression – 9/10 cut-off



EPDS-Postnatal-Major depression - 12/13 cut-off



1.1.2 Depression: PHQ – Sensitivity and Specificity

PHQ – All versions, timings and cut-offs

PHQ-9 (simple)- Postnatal- major depression- 10 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
FLYNN2011	68	8	8	15	No risk	Cohort	Developed	0.89 [0.80, 0.95]	0.65 [0.43, 0.84]		
GJERDINCJEN2009	37	74	8	387	No risk	Cohort	Developed	0.82 [0.68, 0.92]	0.84 [0.80, 0.87]		

PHQ-9- (complex)- Postnatal - major depression- 10 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
GJERDINCJEN2009	30	37	15	424	No risk	Cohort	Developed	0.67 [0.51, 0.80]	0.92 [0.89, 0.94]		

PHQ-9 (simple)- Antenatal- major depression- 10 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
FLYNN2011	43	3	15	8	No risk	Cohort	Developed	0.74 [0.61, 0.85]	0.73 [0.39, 0.94]		
SIDEBOTTOM2012	23	115	4	603	No risk	Cohort	Developed	0.85 [0.66, 0.96]	0.84 [0.81, 0.87]		

PHQ-9 (simple)- Antenatal- mixed depression- 10 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SIDEBOTTOM2012	59	80	20	586	No risk	Cohort	Developed	0.75 [0.64, 0.84]	0.88 [0.85, 0.90]		

PHQ-2- Postnatal- major depression- cut off 3

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
GJERDINCJEN2009	38	97	7	364	No risk	Cohort	Developed	0.84 [0.71, 0.94]	0.79 [0.75, 0.83]		
SMITH2010	10	82	3	118	No risk	Cohort	Developed	0.77 [0.46, 0.95]	0.59 [0.52, 0.66]		

PHQ-2- Postnatal- major depression- cut 4

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SMITH2010	8	42	5	158	No risk	Cohort	Developed	0.62 [0.32, 0.86]	0.79 [0.73, 0.84]		

PHQ-8- Postnatal- Major depression- 10 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SMITH2010	10	76	3	124	No risk	Cohort	Developed	0.77 [0.46, 0.95]	0.62 [0.55, 0.69]		

1.1.3 Depression – Whooley Questions: Sensitivity and Specificity

Whooley Questions – All versions, timings and cut-offs

Whooley Questions- Postnatal- Major depression

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
GJERDINCJEN2009	45	258	0	203	No risk	Cohort	Developed	1.00 [0.92, 1.00]	0.44 [0.39, 0.49]		

Whooley questions- Postnatal- Mixed depression

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
MANN2012	18	27	0	49	No risk	Cohort	Developed	1.00 [0.81, 1.00]	0.64 [0.53, 0.75]		

Whooley questions (+help qn)- Postnatal- mixed depression

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
MANN2012	7	0	11	27	No risk	Cohort	Developed	0.39 [0.17, 0.64]	1.00 [0.87, 1.00]		

Whooley questions- Antenatal- mixed depression

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
MANN2012	17	35	0	74	No risk	Cohort	Developed	1.00 [0.80, 1.00]	0.68 [0.58, 0.77]		

Whooley questions (+ help qn)- Antenatal- mixed depression

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
MANN2012	10	3	7	32	No risk	Cohort	Developed	0.59 [0.33, 0.82]	0.91 [0.77, 0.98]		

1.1.4 Depression: Kessler-10 – Sensitivity and Specificity

Kessler-10 – PHQ – All versions, timings and cut-offs

Kessler-10- Antenatal- major depression - 6 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
FERNANDES2011	28	32	0	134	No risk	Cohort	Developing	1.00 [0.88, 1.00]	0.81 [0.74, 0.86]		
SPIES2009	12	52	4	61	No risk	Cohort	Developing	0.75 [0.48, 0.93]	0.54 [0.44, 0.63]		

Kessler-10- Postnatal- mixed depression 6 cut off


Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
BAGGALEY2007	23	20	4	14	At risk	Cohort	Developing	0.85 [0.66, 0.96]	0.41 [0.25, 0.59]		

1.1.5 Anxiety: EPDS – Sensitivity and Specificity

EPDS – All versions, timings and cut-offs


EPDS- Postnatal- Anxiety disorder- 3/4 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
MATTHEY2008	13	95	5	125	No risk	Cohort	Developed	0.72 [0.47, 0.90]	0.57 [0.50, 0.63]
PHILLIPS2009	36	32	21	76	No risk	Cohort	Developed	0.63 [0.49, 0.76]	0.70 [0.61, 0.79]




EPDS- Postnatal- Anxiety disorder- 4/5 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
MATTHEY2008	12	59	6	161	No risk	Cohort	Developed	0.67 [0.41, 0.87]	0.73 [0.67, 0.79]
PHILLIPS2009	27	11	30	97	No risk	Cohort	Developed	0.47 [0.34, 0.61]	0.90 [0.83, 0.95]




EPDS- Postnatal- anxiety disorder- 5/6 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
MATTHEY2008	12	26	6	194	No risk	Cohort	Developed	0.67 [0.41, 0.87]	0.88 [0.83, 0.92]
PHILLIPS2009	15	11	42	97	No risk	Cohort	Developed	0.26 [0.16, 0.40]	0.90 [0.83, 0.95]




EPDS (full scale)- Antenatal- anxiety disorders- 8/9 cut-off (optimal)

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
THIAGAYSON2013	20	56	5	119	No risk	Cohort	Developed	0.80 [0.59, 0.93]	0.68 [0.61, 0.75]




EPDS- Antenatal and postnatal- CMHD- 2/3 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
TRAN2011	80	92	29	163	No risk	Cohort	Developed	0.73 [0.64, 0.81]	0.64 [0.58, 0.70]




EPDS- Antenatal and postnatal- CMHD- 3/4 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
TRAN2011	76	69	33	186	No risk	Cohort	Developed	0.70 [0.60, 0.78]	0.73 [0.67, 0.78]




EPDS- Antenatal and postnatal- CMHD- 4/5 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
TRAN2011	69	48	40	207	No risk	Cohort	Developed	0.63 [0.54, 0.72]	0.81 [0.76, 0.86]



EPDS- Antenatal and postnatal- CMHD- 5/6 cut-off

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)
TRAN2011	55	35	54	220	No risk	Cohort	Developed	0.50 [0.41, 0.60]	0.86 [0.81, 0.90]



1.1.6 Anxiety: Kessler-10 – Sensitivity and Specificity

Kessler-10 – All versions, timings and cut-offs

Kessler-10- Antenatal- anxiety (panic disorder)

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SPIES2009	1	3	1	124	No risk	Cohort	Developed	0.50 [0.01, 0.99]	0.98 [0.93, 1.00]		

Kessler-10- Antenatal- anxiety (social anxiety)

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SPIES2009	1	32	0	96	No risk	Cohort	Developed	1.00 [0.03, 1.00]	0.75 [0.67, 0.82]		


Kessler-10- Antenatal- Anxiety (PTSD)

Study	TP	FP	FN	TN	Risk factors	Design	Country	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
SPIES2009	2	25	2	100	No risk	Cohort	Developed	0.50 [0.07, 0.93]	0.80 [0.72, 0.87]		

1.2 PSYCHOSOCIAL INTERVENTIONS: PREVENTION (RISK FACTORS IDENTIFIED)


1.2.1 Depression: Post-miscarriage self-help versus TAU

Depression mean symptoms Post-treatment – ITT analysis (at-risk populations)




1.2.2 Depression: Social support versus TAU

Depression diagnosis Post-treatment – ITT analysis (at-risk populations)




Depression diagnosis Post-treatment – Available case analysis (at-risk populations)




1.2.3 Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU


Depression diagnosis Post-treatment – ITT analysis (at-risk populations)




Depression diagnosis Post-treatment – Available case analysis (at-risk populations)




Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)




Depression mean scores Post-treatment – Available case analysis (at-risk populations)




Depression diagnosis Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)




Depression diagnosis Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)



Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.4 Depression: Psychoeducational booklet versus TAU or Enhanced TAU

Depression symptomatology Post-treatment) – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)



Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)




Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)



Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)




Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.5 Depression: Non-mental health-focused education and support versus TAU or Enhanced TAU


Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)



Depression mean scores Post-treatment – ITT analysis (at-risk populations)




Depression mean scores Post-treatment - Available case analysis (at-risk populations)




Depression symptomatology Short Follow-up (9-16 weeks post-intervention) - ITT analysis (at-risk populations)




Depression symptomatology Short Follow-up (9-16 weeks post-intervention) - Available case analysis (at-risk populations)




Depression mean scores Short Follow-up (9-16 weeks post-intervention) - Available case analysis (at-risk populations)




Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)



Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Depression mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.6 Depression: Home visits versus TAU


Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)




Depression mean scores Post-treatment – Available case analysis (at-risk populations)




Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – ITT analysis (at-risk populations)



Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)




Depression mean scores Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.7 Depression: Post-delivery discussion versus Enhanced TAU


Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)



Depression mean scores Post-treatment - Available case analysis (at-risk populations)




Depression symptomatology Very long Follow-up (>104 weeks post-intervention) - ITT analysis (at-risk populations)



Depression symptomatology Very long Follow-up (>104 weeks post-intervention) - Available case analysis (at-risk populations)




Depression mean scores Very long Follow-up (>104 weeks post-intervention) - Available case analysis (at-risk populations)




1.2.8 Depression: Mother-infant relationship interventions versus TAU


Depression diagnosis Post-treatment – ITT analysis (at-risk populations)



Depression diagnosis Post-treatment – Available case analysis (at-risk populations)




Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment – Available case analysis (at-risk populations)




Depression mean scores Post-treatment - Available case analysis (at-risk populations)




Depression mean scores Short Follow-up (9-16 weeks post-intervention) - Available case analysis (at-risk populations)




Depression diagnosis Long Follow-up (25-103 weeks post-intervention) - ITT analysis (at-risk populations)




Depression diagnosis Long Follow-up (25-103 weeks post-intervention) - Available case analysis (at-risk populations)




Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Depression mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.9 Depression: Case management and individualised treatment versus TAU

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)




Depression symptomatology Post-treatment - Available case analysis (at-risk populations)




1.2.10 Anxiety: Post-miscarriage self-help versus TAU

Anxiety mean scores Post-treatment - ITT analysis (at-risk populations)




1.2.11 Anxiety: Non-mental health-focused education and support versus TAU or Enhanced TAU


Anxiety symptomatology Post-treatment - ITT analysis (at-risk populations)




Anxiety symptomatology Post-treatment - Available case analysis (at-risk populations)




Anxiety mean scores Post-treatment – Available case analysis (at-risk populations)




Anxiety symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)




Anxiety symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)



Anxiety mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)




Anxiety symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)



Anxiety symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)



Anxiety mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.12 Anxiety: Home visits versus TAU


Anxiety symptomatology Post-treatment – ITT analysis (at-risk populations)




Anxiety symptomatology Post-treatment – Available case analysis (at-risk populations)




Anxiety mean scores Post-treatment – Available case analysis (at-risk populations)




Anxiety symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Anxiety symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)



Anxiety mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.13 PTSD: Post-miscarriage self-help versus TAU

PTSD symptomatology Post-treatment – ITT analysis (at-risk populations)




PTSD mean scores Post-treatment – ITT analysis (at-risk populations)




1.2.14 General mental health: Post-miscarriage self-help versus TAU

General mental health mean scores Post-treatment – ITT analysis (at-risk populations)




1.2.15 General mental health: Home visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)




1.2.16 General mental health: Post-delivery discussion versus Enhanced TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)




General mental health mean scores Very long follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.17 General mental health: Mother-infant relationship interventions versus TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)




General mental health mean scores Long follow-up (25-104 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.18 Mother-infant attachment: Non-mental health-focused education and support versus TAU or Enhanced TAU


Mother-infant attachment problems Post-treatment – ITT analysis (at-risk populations)




Mother-infant attachment problems Post-treatment – Available case analysis (at-risk populations)




Positive mother-infant interaction mean scores Post-treatment – Available case analysis (at-risk populations)




Maternal sensitivity mean scores Post-treatment - Available case analysis (at-risk populations)



Maternal confidence mean scores Post-treatment - Available case analysis (at-risk populations)



Mother-infant attachment problems Short Follow-up (9-16 weeks post-intervention) - ITT analysis (at-risk populations)




Mother-infant attachment problems Short Follow-up (9-16 weeks post-intervention) - Available case analysis (at-risk populations)



Mother-infant attachment problems Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)




Mother-infant attachment problems Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.19 Mother-infant attachment: Home visits versus TAU


Maternal sensitivity mean scores Post-treatment – Available case analysis (at-risk populations)



Infant involvement mean scores Post-treatment – Available case analysis (at-risk populations)



Discontinued breastfeeding <6 months – ITT analysis (at-risk populations)




1.2.20 Mother-infant attachment: Mother-infant relationship interventions versus TAU


Mother-infant attachment problems Post-treatment – ITT analysis (at-risk populations)




Mother-infant attachment problems Post-treatment – Available case analysis (at-risk populations)




Positive mother-infant interaction mean scores Post-treatment – Available case analysis (at-risk populations)




Maternal sensitivity mean scores Post-treatment – Available case analysis (at-risk populations)




Maternal intrusiveness mean scores Post-treatment – Available case analysis (at-risk populations)




Maternal negative engagement mean scores Post-treatment – Available case analysis (at-risk populations)




Infant involvement mean scores Post-treatment – Available case analysis (at-risk populations)




Infant responsivity mean scores Post-treatment – Available case analysis (at-risk populations)




Infant negative engagement/behaviour problems mean score Post-treatment – Available case analysis (at-risk populations)



Discontinued breastfeeding <6 months – ITT analysis (at-risk populations)




Discontinued breastfeeding <6 months – Available case analysis (at-risk populations)



Discontinued breastfeeding <9 months – ITT analysis (at-risk populations)



Discontinued breastfeeding <9 months – Available case analysis (at-risk populations)



Discontinued breastfeeding <12 months – ITT analysis (at-risk populations)




Discontinued breastfeeding <12 months – Available case analysis (at-risk populations)




1.2.21 Mother-infant attachment: Case management and individualised treatment versus TAU

Maternal sensitivity Post-treatment – ITT analysis (at-risk populations)




Maternal sensitivity Post-treatment – Available case analysis (at-risk populations)




1.2.22 Quality of life: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Poor social support Post-treatment – ITT analysis (at-risk populations)




Poor social support Post-treatment – Available case (at-risk populations)




1.2.23 Quality of life: Non-mental health-focused education and support versus TAU or Enhanced TAU


Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)




Social support mean scores Post-treatment – Available case analysis (at-risk populations)



Social support mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)




Social support mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.24 Quality of life: Home visits versus TAU

Social support mean scores Post-treatment – Available case analysis (at-risk populations)




Self-esteem mean scores Post-treatment – Available case analysis (at-risk populations)




1.2.25 Quality of life: Mother-infant relationship interventions versus TAU

Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)




Parental stress mean scores Long follow-up (25-104 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.26 Quality of life: Case management and individualised treatment versus TAU


Parental stress mean scores Post-treatment – ITT analysis (at-risk populations)




Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)



Self-esteem mean scores Post-treatment – ITT analysis (at-risk populations)




Self-esteem mean scores Post-treatment – Available case analysis (at-risk populations)




1.2.27 Service utilisation: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Contact with primary and/or secondary care Post-Treatment – ITT analysis (at-risk populations)




Contact with primary and/or secondary care Post-treatment – Available case analysis (at-risk populations)




1.2.28 Service utilisation: Home visits versus TAU

Maternal contact with primary and/or secondary care Post-treatment – ITT analysis (at-risk populations)




Maternal contact with primary and/or secondary care Post-treatment – Available case analysis (at-risk populations)



Infant admissions to hospital Mid-treatment (at 6 months) – ITT analysis (at-risk populations)




Infant length of stay in hospital Mid-treatment (at 6 months) – ITT analysis (at-risk populations)



1.2.29 Experience of care: Non-mental health-focused education and support versus TAU or Enhanced TAU

Maternal dissatisfaction with care Post-treatment – ITT analysis (at-risk populations)




Maternal dissatisfaction with care Post-treatment – Available case analysis (at-risk populations)




1.2.30 Attrition: Post-miscarriage self-help versus TAU

Dropout




1.2.31 Attrition: Social support versus TAU

Dropout




1.2.32 Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Dropout




1.2.33 Attrition: Psychoeducational booklet versus TAU or Enhanced TAU

Dropout



1.2.34 Attrition: Non-mental health-focused education and support versus TAU or Enhanced TAU

Dropout



1.2.35 Attrition: Home visits versus TAU

Dropout




1.2.36 Attrition: Post-delivery discussion versus Enhanced TAU

Dropout




1.2.37 Attrition: Mother-infant relationship interventions versus TAU

Dropout




1.2.38 Infant physical health: Home visits versus TAU


Congenital malformations (measured at 6 months) – Available case analysis (at-risk populations)




Normal weight Post-treatment – Available case analysis (at-risk populations)



Underweight Post-treatment – Available case analysis (at-risk populations)



Overweight Post-treatment – Available case analysis (at-risk populations)




Incidence of severe diarrhoea Post-treatment – Available case analysis (at-risk populations)




1.2.39 Infant regulatory problems: Mother-infant relationship interventions versus TAU


Infant colic mean scores Post-treatment – Available case analysis (at-risk populations)




Infant sleep problems mean score Post-treatment – Available case analysis (at-risk populations)




Infant excessive crying mean scores Post-treatment – Available case analysis (at-risk populations)




Infant colic mean scores Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)



Infant sleep problems mean score Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)




Infant excessive crying mean scores Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.40 Infant physical development: Home visits versus TAU


Infant motor development (delayed or impaired) Post-treatment – ITT analysis (at-risk populations)




Infant motor development (delayed or impaired) Post-treatment – Available case analysis (at-risk populations)




Infant motor development mean scores Post-treatment – Available case analysis (at-risk populations)




Infant motor development (delayed or impaired) Long follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Infant motor development (delayed or impaired) Long follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant motor development mean scores Long follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.41 Infant cognitive development: Home visits versus TAU


Infant cognitive development (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant cognitive development (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant cognitive development mean scores Post-treatment – Available case analysis (at-risk populations)




Infant verbal development (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant verbal development (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant verbal development mean scores Post-treatment – Available case analysis (at-risk populations)




Infant nonverbal development (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant nonverbal development (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant nonverbal development mean scores Post-treatment – Available case analysis (at-risk populations)




Infant spatial reasoning development (impairment) Post-treatment - ITT analysis (at-risk populations)




Infant spatial reasoning development (impairment) Post-treatment - Available case analysis (at-risk populations)




Infant spatial reasoning development mean scores Post-treatment - Available case analysis (at-risk populations)




Infant cognitive development (impairment) Long Follow-up (25-103 weeks post-intervention) - ITT analysis (at-risk populations)




Infant cognitive development (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant cognitive development mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant verbal development (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Infant verbal development (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant verbal development mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.42 Infant emotional development: Home visits versus TAU


Infant adaptive behaviour (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant adaptive behaviour (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant adaptive behaviour mean scores Post-treatment – Available case analysis (at-risk populations)




Infant emotional development (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant emotional development (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant externalising (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant externalising (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant externalising mean scores Post-treatment - Available case analysis (at-risk populations)




Infant internalising (impairment) Post-treatment - ITT analysis (at-risk populations)




Infant internalising (impairment) Post-treatment - Available case analysis (at-risk populations)




Infant internalising mean scores Post-treatment - Available case analysis (at-risk populations)




Infant dysregulation (impairment) Post-treatment – ITT analysis (at-risk populations)




Infant dysregulation (impairment) Post-treatment – Available case analysis (at-risk populations)




Infant dysregulation mean scores Post-treatment – Available case analysis (at-risk populations)




Infant adaptive behaviour (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)




Infant adaptive behaviour (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant adaptive behaviour mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant externalising (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)




Infant externalising (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant externalising mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant internalising (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)



Infant internalising (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




Infant internalising mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)




1.2.43 Infant emotional development: Mother-infant relationship interventions versus TAU


Infant social-communication development mean scores Post-treatment - Available case analysis (at-risk populations)



Infant social withdrawal mean scores Post-treatment - Available case analysis (at-risk populations)




Infant social withdrawal mean scores Short follow-up (9-16 weeks post-intervention) - Available case analysis (at-risk populations)



1.2.44 Prevention of neglect or abuse of the infant: Home visits versus TAU


Child protection issues Post-treatment - ITT analysis (at-risk populations)




Child removed from home Post-treatment - ITT analysis (at-risk populations)



Infant mortality Post-treatment - ITT analysis (at-risk populations)




Infant abuse or neglect Post-treatment - Available case analysis (at-risk populations)




1.3 PROTOCOLS FOR WOMEN FOLLOWING STILLBIRTH

1.3.1 Mental health outcomes for women who saw versus did not see their stillborn infant


Depression symptomatology




Depression mean symptoms




Anxiety symptomatology




Anxiety mean symptoms




PTSD symptomatology



PTSD mean symptoms




Overall adverse outcome




1.3.2 Mental health outcomes for women who held versus did not hold their stillborn infant


Depression symptomatology




Depression mean symptoms




Anxiety symptomatology




Anxiety mean symptoms




PTSD/PTSS symptomatology



PTSD mean symptoms




Overall adverse outcome




1.3.3 Mental health outcomes for women who spent as much time with stillborn infant as they wished versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)



1.3.4 Mental health outcomes for women who kept a photo of their stillborn infant versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)




1.3.5 Mental health outcomes for women who kept a token of remembrance of their stillborn infant versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)



1.3.6 Mental health outcomes for women who took drug to stop milk production following stillbirth versus those who did not


Depression (3-years post-stillbirth; CES-D>90th percentile)




1.4 PSYCHOSOCIAL INTERVENTIONS: PREVENTION (NO RISK FACTORS IDENTIFIED)

1.4.1 Depression: Structured psychological interventions (CBT or IPT) versus TAU


Depression symptomatology Post-treatment - ITT analysis (no-risk populations)



Depression symptomatology Post-treatment – Available case analysis (no-risk populations)




Depression mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.2 Depression: Listening visits versus TAU


Depression symptomatology Post-treatment – ITT analysis (no-risk populations)



Depression symptomatology Post-treatment – Available case analysis (no-risk populations)




Depression mean scores Post-treatment - Available case analysis (no-risk populations)




1.4.3 Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU


Depression symptomatology Post-treatment - ITT analysis (no-risk populations)




Depression symptomatology Post-treatment - Available case analysis (no-risk populations)




Depression symptomatology Short Follow-up (9-16 weeks post-intervention) - ITT analysis (no-risk populations)




Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (no-risk populations)



Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (no-risk populations)




Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (no-risk populations)




1.4.4 Depression: Home visits versus TAU

Depression mean scores Post-treatment – Available case analysis (no-risk populations)




Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)




1.4.5 Depression: Post-delivery discussion versus TAU

Depression symptomatology Post-treatment – Available case analysis (no-risk populations)




1.4.6 Depression: Mother-infant relationship interventions versus Enhanced TAU

Depression mean scores Post-treatment – ITT analysis (no-risk populations)




Depression mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.7 Depression: Mindfulness training versus TAU

Depression mean scores Post-treatment - Available case analysis (no-risk populations)




1.4.8 Anxiety: Structured psychological interventions (CBT or IPT) versus TAU

Anxiety mean scores Post-treatment - Available case analysis (no-risk populations)




Trait anxiety mean scores Post-treatment - Available case analysis (no-risk populations)




1.4.9 Anxiety: Listening visits versus TAU

Anxiety mean scores Post-treatment - Available case analysis (no-risk populations)




Trait anxiety mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.10 Anxiety: Post-delivery discussion versus TAU

Anxiety symptomatology Post-treatment – Available case analysis (no-risk populations)




1.4.11 Anxiety: Music therapy versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.12 Anxiety: Mindfulness training versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.13 General mental health: Structured psychological interventions (CBT or IPT) versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)




Risk of self-harm mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.14 General mental health: Listening visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)




Risk of self-harm mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.15 General mental health: Home visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)




General mental health mean scores Intermediate follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)




1.4.16 General mental health: Mindfulness training versus TAU


Psychological distress mean scores Post-treatment – Available case analysis (no-risk populations)



Life satisfaction mean scores Post-treatment – Available case analysis (no-risk populations)




Happiness mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.17 Mother-infant attachment: Home visits versus TAU

Discontinued breastfeeding by 6 weeks – Available case analysis (no-risk populations)




Discontinued breastfeeding by 26 weeks – Available case analysis (no-risk populations)




1.4.18 Mother-infant attachment: Mother-infant relationship interventions versus Enhanced TAU


Maternal sensitivity mean scores Post-treatment – ITT analysis (no-risk populations)




Maternal sensitivity mean scores Post-treatment – Available case analysis (no-risk populations)




Child attachment security mean scores Post-treatment – ITT analysis (no-risk populations)




Child attachment security mean scores Post-treatment – Available case analysis (no-risk populations)



Maternal confidence/competence mean scores Post-treatment – ITT analysis (no-risk populations)




Maternal confidence/competence mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.19 Mother-infant attachment: Mindfulness training versus TAU

Maternal confidence/competence mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.20 Quality of life: Structured psychological interventions (CBT or IPT) versus TAU


Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)



Impaired functioning mean scores Post-treatment – Available case analysis (no-risk populations)




Wellbeing mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.21 Quality of life: Listening visits versus TAU


Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)



Impaired functioning mean scores Post-treatment – Available case analysis (no-risk populations)




Wellbeing mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.22 Quality of life: Home visits versus TAU

Social support mean scores Post-treatment – Available case analysis (no-risk populations)




Social support mean scores Intermediate follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)




1.4.23 Quality of life: Mother-infant relationship interventions versus Enhanced TAU

Parental stress mean scores Post-treatment – ITT analysis (no-risk populations)




Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)




1.4.24 Quality of life: Music therapy versus TAU

Parental stress mean scores Post-treatment - Available case analysis (no-risk populations)




1.4.25 Quality of life: Mindfulness training versus TAU

Parental stress mean scores Post-treatment - Available case analysis (no-risk populations)




1.4.26 Attrition: Structured psychological interventions (CBT or IPT) versus TAU

Dropout



1.4.27 Attrition: Listening visits versus TAU

Dropout



1.4.28 Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus Enhanced TAU

Dropout




1.4.29 Attrition: Home visits versus TAU

Dropout



1.4.30 Attrition: Mindfulness training versus TAU


Dropout




1.5 PSYCHOSOCIAL INTERVENTIONS: TREATMENT

1.5.1 Depression: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




Depression Short Follow-up (diagnosis at 9-16 week follow-up) – ITT analysis




Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – ITT analysis




Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – Available case analysis




Depression Short Follow-up (mean depression symptoms at 9-16 week follow-up) – ITT analysis




Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis



Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis




Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – ITT analysis




Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – Available case analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis




Depression Very long Follow-up (diagnosis at >104 week follow-up) - ITT analysis




Depression Very long Follow-up (diagnosis at >104 week follow-up) - Available case analysis



Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) - Available case analysis




Negative thoughts/mood Post-treatment (mean score at endpoint or first measurement) - Available case analysis




1.5.2 Depression: CBT versus listening visits

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis




1.5.3 Depression: CBT versus Relational Constructivist Therapy

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis




1.5.4 Depression: IPT versus support group

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis




1.5.5 Depression: Facilitated self-help versus TAU


Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT Analysis



Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




1.5.6 Depression: Post-miscarriage self-help versus TAU


Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis




1.5.7 Depression: Post-miscarriage facilitated self-help versus TAU

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis




1.5.8 Depression: Directive counselling versus TAU


Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis



Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis



1.5.9 Depression: Listening visits versus TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis



Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – by intervention




Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis




Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – ITT analysis




Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – Available case analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis




Depression Very long Follow-up (diagnosis at >104 week follow-up) – ITT analysis



Depression Very long Follow-up (diagnosis at >104 week follow-up) – Available case analysis




Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) – Available case analysis




1.5.10 Depression: Post-miscarriage counselling versus TAU


Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis



Depression Intermediate follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis




1.5.11 Depression: Post-traumatic birth counselling versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




1.5.12 Depression: Social support versus TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – ITT analysis



Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – Available case analysis




Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis




1.5.13 Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




Depression Short Follow-up (mean depression symptoms at 9-16 week follow-up) – ITT analysis




Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis




Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis



Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis



Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis




1.5.14 Depression: IPT-informed psychoeducation versus non-mental health-focused education and support

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT Analysis




1.5.15 Depression: Non-mental health-focused education and support versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




1.5.16 Depression: Home visits versus TAU/Enhanced TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




1.5.17 Depression: Mother-infant relationship interventions versus TAU/Enhanced TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis



Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis




Depression Intermediate Follow-up (symptomatology – above threshold at 17-24 week follow-up) – ITT analysis




Depression Intermediate Follow-up (symptomatology – above threshold at 17-24 week follow-up) – Available case analysis




Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis




Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis




Depression Very long Follow-up (diagnosis at >104 week follow-up) – ITT analysis



Depression Very long Follow-up (diagnosis at >104 week follow-up) – Available case analysis




Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) – Available case analysis




1.5.18 Depression: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis




1.5.19 Depression: Co-parenting intervention versus Enhanced TAU


Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis



Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




1.5.20 Depression: Infant sleep training (controlled crying) versus TAU/Enhanced TAU


Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis



Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis




Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis



1.5.21 Depression: Music therapy during birth versus TAU


Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




1.5.22 Depression: Psychosomatic intervention versus TAU


Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) - ITT analysis



Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) - Available case analysis




Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) - Available case analysis




1.5.23 Depression: Mindfulness training versus Enhanced TAU

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) - Available case analysis




Negative affect Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis




1.5.24 Anxiety: Structured psychological interventions versus TAU/Enhanced TAU


Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – ITT analysis



Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




Trait anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.25 Anxiety: CBT versus Relational Constructivist Therapy

Anxiety Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.26 Anxiety: IPT versus support group

Anxiety Post-treatment (mean score at endpoint or first measurement) – Available case



1.5.27 Anxiety: Facilitated self-help versus TAU


Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.28 Anxiety: Post-miscarriage self-help versus TAU


Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – ITT analysis




1.5.29 Anxiety: Listening visits versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




Trait anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.30 Anxiety: Directive counselling versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.31 Anxiety: Post-miscarriage counselling versus Enhanced TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




Anxiety Intermediate follow-up (mean anxiety symptoms at 17-24 week follow-up) – Available case analysis




1.5.32 Anxiety: Post-traumatic birth counselling versus TAU

Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



1.5.33 Anxiety: Social support versus TAU


Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




Anxiety Short follow-up (mean anxiety symptoms at 9-16 week follow-up) – Available case analysis




1.5.34 Anxiety: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


Anxiety Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis



Anxiety Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




Anxiety Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis




1.5.35 Anxiety: Mother-infant relationship interventions versus TAU/Enhanced TAU


Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




Anxiety Intermediate follow-up (mean anxiety symptoms at 17-24 week follow-up) – Available case analysis




1.5.36 Anxiety: Music therapy during birth versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.37 Anxiety: Psychosomatic intervention versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.38 Anxiety: Mindfulness training versus Enhanced TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – ITT analysis




Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis




1.5.39 Adjustment disorder: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU

Adjustment disorders Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Adjustment disorders Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




1.5.40 PTSD: Post-miscarriage self-help versus TAU


PTSD Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis



PTSD Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis



PTSD Post-treatment (mean score at endpoint or first measurement) – ITT analysis




1.5.41 PTSD: Post-traumatic birth counselling versus TAU


PTSD Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




PTSD Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis



PTSD Post-treatment (mean score at endpoint or first measurement) – ITT analysis




PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.42 PTSD: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


PTSD Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis



PTSD Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.43 PTSD: Mother-infant relationship interventions versus TAU/Enhanced TAU


PTSD Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis




PTSD Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis




PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis




PTSD Intermediate follow-up (symptomatology at 17-24 week follow-up) – ITT analysis



PTSD Intermediate follow-up (symptomatology at 17-24 week follow-up) – Available case analysis




PTSD Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




1.5.44 OCD: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


OCD Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Obsessions Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Compulsions Post-treatment (mean score at endpoint or first measurement) – Available case analysis




OCD Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Obsessions Intermediate follow-up (mean score at 17-24 week follow-up) - Available case analysis




Compulsions Intermediate follow-up (mean score at 17-24 week follow-up) - Available case analysis




OCD Long follow-up (mean score at >24 week follow-up) - Available case analysis



Obsessions Long follow-up (mean score at >24 week follow-up) - Available case analysis



Compulsions Long follow-up (mean score at >24 week follow-up) - Available case analysis




1.5.45 Fear of childbirth: Pre-delivery discussion/psychoeducation versus TAU


Elective caesarean Post-treatment (mode of delivery at endpoint) - ITT analysis




Choosing vaginal delivery Post-treatment (delivery preference at endpoint) – ITT analysis




Vaginal delivery Post-treatment (mode of delivery at endpoint) – ITT analysis




Fear of pain in labour Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – ITT analysis




Fear of obstetrician's unfriendly behaviour Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – ITT analysis




Preparedness for childbirth Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – Available case analysis




Satisfaction with childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Feeling safe during childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis



Experience of fear during childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Maternal attitude to motherhood Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.46 Eating disorder: Mother-infant relationship interventions (and guided self-help) versus listening visits (and guided self-help)

Eating disorder Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Eating disorder Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis




1.5.47 General mental health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU


General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis




General mental health (higher better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis




Risk of self-harm Post-treatment (mean score at endpoint or first measurement) – Available case analysis



General mental health Short follow-up (mean mental health symptoms at 9-16 week follow-up) – ITT analysis




General mental health Intermediate follow-up (mean mental health symptoms at 17-24 week follow-up) – Available case analysis




1.5.48 General mental health: IPT versus support group

Anger Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.49 General mental health: Post-miscarriage self-help versus TAU


General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis



General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis




General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis




1.5.50 General mental health: Listening visits versus TAU

General mental health (higher better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis




Risk of self-harm Post-treatment (mean score at endpoint or first

measurement) – Available case analysis




1.5.51 General mental health: Post-miscarriage counselling versus TAU

Self-blame Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Self-blame Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




1.5.52 General mental health: Post-traumatic birth counselling versus TAU

Self-blame Post-treatment (feelings of self-blame at endpoint or first measurement) – ITT analysis




Self-blame Post-treatment (feelings of self-blame at endpoint or first measurement) – Available case analysis




1.5.53 General mental health: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


Any psychopathology Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis




Any psychopathology Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis



General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis




General mental health Short follow-up (mean mental health symptoms at 9-16 week follow-up) – ITT analysis




1.5.54 General mental health: Home visits versus TAU/Enhanced TAU


General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis




General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis



Alcohol or drug use Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis




Alcohol or drug use Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis




1.5.55 General mental health: Mother-infant relationship interventions versus TAU/Enhanced TAU


General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis



General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis




General mental health (lower better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis




1.5.56 General mental health: Co-parenting intervention versus Enhanced TAU

Psychological distress Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.57 Mother-infant attachment: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU


Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




Mother-infant attachment Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Mother-infant play frequency Post-treatment (mothers played with infant once or more every day measured at endpoint or first measurement) – ITT analysis




Mother-infant play frequency Post-treatment (mothers played with infant once or more every day measured at endpoint or first measurement) – Available case analysis




Maternal sensitivity Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – ITT analysis



Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – Available case analysis




Mother-infant attachment Short follow-up (mean score at 9-16 week follow-up) – Available case analysis



Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis




Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case analysis




1.558 Mother-infant attachment: Facilitated self-help versus TAU

Maternal attitude towards motherhood Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.559 Mother-infant attachment: Listening visits versus TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis



Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – ITT analysis



Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – Available case analysis



Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis




Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case analysis




1.5.60 Mother-infant attachment: Social support versus TAU

Mother-infant feeding interaction Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Mother-infant teaching interaction Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.61 Mother-infant attachment: Psychologically (CBT/IPT) – informed psychoeducation versus Enhanced TAU

Maternal competence/confidence Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Maternal competence/confidence Short follow-up (mean score at 9-16 week follow-up) – Available case analysis



1.5.62 Mother-infant attachment: Home visits versus TAU/Enhanced TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




1.5.63 Mother-infant attachment: Mother-infant relationship interventions versus TAU/Enhanced TAU


Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




Mother-infant attachment/positive interactions Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Maternal sensitivity Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Maternal sensitivity Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Maternal sensitivity Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Maternal structuring Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Maternal structuring Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Maternal structuring Post-treatment (mean score at endpoint or first measurement) – Available case analysis



Maternal nonintrusiveness Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Maternal nonintrusiveness Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Maternal nonintrusive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Maternal intrusive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Maternal nonhostility Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Child responsiveness Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Child responsiveness Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Child responsiveness Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Child involvement Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Child involvement Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Child involvement/positive engagement Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Child attachment security Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis




Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis




Maternal confidence/competence Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Mother-infant positive interaction Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Maternal sensitivity Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Maternal intrusive behaviour Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis




Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case




Maternal sensitivity Long follow-up (mean score at >24 week follow-up) - Available case analysis




Maternal structuring Long follow-up (mean score at >24 week follow-up) - Available case analysis




Maternal nonintrusive behaviour Long follow-up (mean score at >24 week follow-up) - Available case analysis




Maternal nonhostility Long follow-up (mean score at >24 week follow-up) - Available case analysis




Child responsiveness Long follow-up (mean score at >24 week follow-up) - Available case analysis




Child involvement Long follow-up (mean score at >24 week follow-up) - Available case analysis



Mother-infant attachment/positive interactions Very long follow-up (mean score at >104 week follow-up) - Available case analysis




Child attachment security Very long follow-up (mean score at >104 week follow-up) - Available case analysis




1.5.64 Mother-infant attachment: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Maternal confidence Post-treatment (mean scores at endpoint or first measurement) - Available case analysis




Maternal perceptions of infant behaviour Post-treatment (mean scores at endpoint or first measurement) – Available case analysis




1.5.65 Mother-infant attachment: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)


Mealtime conflict Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis




Mealtime conflict Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis




Maternal inappropriate verbal responses Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis




Maternal inappropriate verbal responses Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis




Maternal intrusions Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis




Maternal intrusions Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis



Infant autonomy Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis




Infant autonomy Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis




1.5.66 Quality of life: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU


Social support Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Life functioning Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Life functioning Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Wellbeing Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Social support Short follow-up (mean score at 9-16 week follow-up) - ITT analysis



Social support Short follow-up (mean score at 9-16 week follow-up) - Available case analysis




Life functioning Short follow-up (mean score at 9-16 week follow-up) - ITT analysis




1.5.67 Quality of life: IPT versus support group

Maternal cortisol level Post-treatment (mean score at endpoint or first measurement) - Available case analysis




1.5.68 Quality of life: Facilitated self-help versus TAU


Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available analysis



Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis




Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis




1.5.69 Quality of life: Listening visits versus TAU


Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis



Wellbeing Post-treatment (improved wellbeing at endpoint or first measurement) – Available case analysis




Wellbeing Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.70 Quality of life: Directive counselling versus TAU

Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




1.5.71 Quality of life: Post-miscarriage counselling versus TAU

Functional impairment Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.72 Quality of life: Post-traumatic birth counselling versus TAU

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis




Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis




1.5.73 Quality of life: Social support versus TAU


Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Maternal cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Self-esteem Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis



Loneliness Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Loneliness Short follow-up (mean score at 9-16 week follow-up) – Available case analysis




1.5.74 Quality of life: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


Social support Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




Maternal cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Happiness Post-treatment (mean score at endpoint or first measurement) – ITT analysis




Social support Short follow-up (mean score at 9-16 week follow-up) – ITT analysis




Functional impairment Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Parental stress Intermediate follow-up (mean score at 17-24 week follow-up) – ITT analysis




Parental stress Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis




Happiness Intermediate follow-up (mean score at 17-24 week follow-up) – ITT analysis



Parental stress Long follow-up (mean score at >24 week follow-up) – Available case analysis




Maternal cortisol levels Long follow-up (mean score at >24 week follow-up) – Available case analysis




1.5.75 Quality of life: Home visits versus TAU/Enhanced TAU


Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis



Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis



Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis



1.5.76 Quality of life: Mother-infant relationship interventions versus TAU/Enhanced TAU


Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis



Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis




1.5.77 Quality of life: Psychosomatic intervention versus TAU

Poor social support Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Parental stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.78 Quality of life: Mindfulness training versus TAU/Enhanced TAU


Parental stress Post-treatment (mean score at endpoint or first measurement) – ITT analysis



Parental stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Positive affect Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.79 Service utilisation: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis



Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis



Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis



Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis



Psychotherapy Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis




Psychotherapy Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis




Counselling Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis



Counselling Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis




Self-help support group Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis



Self-help support group Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis



Alternative therapies Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis



Alternative therapies Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis



1.5.80 Service utilisation: Facilitated self-help versus TAU


Use of childbirth hospital Post-Treatment (service utilisation at endpoint) – ITT analysis



Use of childbirth hospital Post-Treatment (service utilisation at endpoint) - Available case analysis




Use of childbirth hospital Post-Treatment (service utilisation at endpoint) - Available case analysis




Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) - ITT analysis




Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) - Available case analysis




Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis




Use of mental health hospital Post-Treatment (service utilisation at endpoint) – ITT analysis



Use of mental health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis



Use of mental health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis




Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – ITT analysis




Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – Available case analysis




Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – Available case analysis




Use of health community service Post-Treatment (service utilisation at endpoint) – ITT analysis




Use of health community service Post-Treatment (service utilisation at endpoint) – Available case analysis




Use of health community service Post-Treatment (service utilisation at endpoint) – Available case analysis




Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis



Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis




Antidepressant medication Post-Treatment (medication use at endpoint) – Available case analysis



1.5.81 Service utilisation: Listening visits versus TAU


Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – ITT analysis



Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis



Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis




Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis




Health visitor telephone contact Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis



Health visitor telephone contact Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis



Maternal use of midwife Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis




Maternal use of midwife Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis



Use of GP Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis




Use of GP Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis



1.5.82 Service utilisation: Social support versus TAU


Health service use Post-Treatment (service utilisation at endpoint) – Available case analysis




Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis




Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis



Health service use Short follow-up (service utilisation at 9-16 week follow-up) – Available case analysis



Antidepressant medication Short follow-up (medication use at 9-16 week follow-up) – ITT analysis




Antidepressant medication Short follow-up (medication use at 9-16 week follow-up) – Available case analysis




1.5.83 Experience of care: Mother-infant relationship interventions versus TAU/Enhanced TAU

Satisfaction with intervention Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Satisfaction with therapeutic alliance (empathetic) Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.84 Attrition: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Dropout




1.5.85 Attrition: CBT versus Relational Constructivist Therapy

Dropout




1.5.86 Attrition: IPT versus support group

Dropout




1.5.87 Attrition: Facilitated self-help versus TAU

Dropout




1.5.88 Attrition: Listening visits versus TAU

Dropout




1.5.89 Attrition: Directive counselling versus TAU

Dropout




1.5.90 Attrition: Post-miscarriage counselling versus TAU/Enhanced TAU

Dropout




1.5.91 Attrition: Post-traumatic birth counselling versus TAU

Dropout




1.5.92 Attrition: Social support versus TAU

Dropout



1.5.93 Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU

Dropout




1.5.94 Attrition: Non-mental health-focused education and support versus TAU

Dropout




1.5.95 Attrition: Home visits versus TAU

Dropout



1.5.96 Attrition: Mother-infant relationship interventions versus TAU/Enhanced TAU

Dropout




1.5.97 Attrition: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Dropout




1.5.98 Attrition: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)

Dropout




1.5.99 Attrition: Co-parenting intervention versus Enhanced TAU

Dropout



1.5.100 Attrition: Music therapy during birth versus TAU

Dropout



1.5.101 Attrition: Psychosomatic intervention versus TAU

Dropout



1.5.102 Attrition: Mindfulness training versus Enhanced TAU

Dropout




1.5.103 Infant service use: Facilitated self-help versus TAU


Infant hospital Post-Treatment (service utilisation at endpoint) - ITT analysis



Infant hospital Post-Treatment (service utilisation at endpoint) - Available case analysis



Infant hospital Post-Treatment (service utilisation at endpoint) - Available case analysis



1.5.104 Infant service use: Listening visits versus TAU


Infant hospital Post-Treatment (service utilisation at endpoint) - ITT analysis




Infant hospital Post-Treatment (service utilisation at endpoint) - Available case analysis



Visit to A&E Post-Treatment (service utilisation measured at endpoint) - ITT analysis




Visit to A&E Post-Treatment (service utilisation measured at endpoint) - Available case analysis




Visit to NHS health visitor at clinic Post-Treatment (service utilisation [in past month] at endpoint) – ITT analysis




Visit to NHS health visitor at clinic Post-Treatment (service utilisation [in past month] at endpoint) – Available case analysis



Visit from NHS health visitor at home Post-Treatment (service utilisation [in past month] at endpoint) – by intervention



Visit from NHS health visitor at home Post-Treatment (service utilisation [in past month] at endpoint) – by intervention



**Visit to GP Post-Treatment (service utilisation [in past month] at endpoint)
– ITT analysis**




**Visit to GP Post-Treatment (service utilisation [in past month] at endpoint)
– Available case analysis**



**Any medication Post-Treatment (medication use [in past week] at endpoint)
– ITT analysis**




**Any medication Post-Treatment (past medication use measured at endpoint)
– by intervention**



Antibiotics Post-Treatment (medication use [in past week] at endpoint) – ITT analysis



Antibiotics Post-Treatment (medication use [in past week] at endpoint) – Available case analysis



Asthma medication Post-Treatment (medication use [in past week] at endpoint) – ITT analysis



Asthma medication Post-Treatment (medication use [in past week] at endpoint) – Available case analysis




Skin ointment Post-Treatment (medication use [in past week] at endpoint) – ITT analysis



Skin ointment Post-Treatment (medication use [in past week] at endpoint) – Available case analysis



Visit to A&E Long follow-up (service utilisation [in past month] at >24 week follow-up) – ITT analysis



Visit to A&E Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis




Visit to NHS health visitor at clinic Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis



Visit to GP Long follow-up (service utilisation [in past month] at >24 week follow-up) – ITT analysis




Visit to GP Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis




1.5.105 Infant service use: Home visits versus TAU


Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis




Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis




Visit to A&E Post-Treatment (service utilisation measured at endpoint) – ITT analysis



Visit to A&E Post-Treatment (service utilisation measured at endpoint) – Available case analysis




Any medication Post-Treatment (past medication use measured at endpoint) – Available case analysis




1.5.106 Infant service use: Mother-infant relationship interventions versus TAU/Enhanced TAU


Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis




Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis




Contact with specialised healthcare services Post-Treatment (service utilisation at endpoint) – ITT analysis




Contact with specialised healthcare services Post-Treatment (service utilisation at endpoint) – Available case analysis




Contact with developmental/rehabilitation specialist Post-Treatment (service utilisation at endpoint) – ITT analysis




Contact with developmental/rehabilitation specialist Post-Treatment (service utilisation at endpoint) – Available case analysis




Any medication Post-Treatment (medication use [in past week] at endpoint) – ITT analysis




Any medication Post-Treatment (past medication use measured at endpoint) – Available case analysis




Surgery Post-Treatment (service utilisation at endpoint) – ITT analysis




Surgery Post-Treatment (service utilisation at endpoint) – Available case analysis



Oxygen therapy Post-Treatment (service utilisation at endpoint) – ITT analysis



Oxygen therapy Post-Treatment (service utilisation at endpoint) – Available case analysis



1.5.107 Infant physical health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU


Underweight Post-treatment (underweight at endpoint or first measurement) – ITT analysis



Underweight Post-treatment (underweight at endpoint or first measurement) – Available case analysis




Weight-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis




Stunted height Post-treatment (short-for-age at endpoint or first measurement) – ITT analysis



Stunted height Post-treatment (short-for-age at endpoint or first measurement) – Available case analysis



Height-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis



Diarrhoea Post-treatment (=>1 diarrhoea episodes [in past 2 weeks] at endpoint or first measurement) – ITT analysis




Diarrhoea Post-treatment (=>1 diarrhoea episodes [in past 2 weeks] at endpoint or first measurement) – Available case analysis




1.5.108 Infant physical health: IPT versus support group

Gestational age Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Birth weight Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.109 Infant physical health: Listening visits versus TAU

Ill health Post-treatment (maternal concerns about child health at endpoint or first measurement) – ITT analysis




Ill health Post-treatment (maternal concerns about child health at endpoint or first measurement) – Available case analysis




1.5.110 Infant physical health: Social support versus TAU

Infant cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.111 Infant physical health: Psychologically (CBT/IPT) – informed psychoeducation versus TAU/Enhanced TAU


Infant stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis



Infant cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant cortisol levels Long follow-up (mean score at >24 week follow-up) – Available case analysis




1.5.112 Infant physical health: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)

Weight-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis




1.5.113 Infant physical development: CBT versus listening visits

Infant motor development Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.114 Infant physical development: Listening visits versus TAU

Infant eating habits Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis



Infant eating habits Post-treatment (maternal concerns at endpoint or first measurement) – Available case analysis



Infant sleeping habits Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis




Infant sleep problems Post-treatment (maternal report at endpoint or first measurement) – Available case analysis




1.5.115 Infant physical development: Home visits versus TAU


Infant motor development Post-treatment (below threshold at endpoint or first measurement) – ITT analysis




Infant motor development Post-treatment (below threshold at endpoint or first measurement) – Available case analysis



Infant feeding problems Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant sleep problems Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.116 Infant physical development: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant motor development Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.117 Infant physical development: Infant sleep training (controlled crying) versus TAU

Infant sleep problems Post-treatment (maternal report at endpoint or first measurement) – Available case analysis



Infant sleep problems Short follow-up (maternal report at 9-16 week follow-up) – Available case analysis




Infant sleep problems Long follow-up (maternal report at >24 week follow-up) – Available case analysis



1.5.118 Infant cognitive development: CBT versus listening visits

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.119 Infant cognitive development: Listening visits versus TAU

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – ITT analysis




Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – Available case analysis



Infant verbal development Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis




Infant verbal development Post-treatment (maternal concerns at endpoint or first measurement) – Available case analysis




1.5.120 Infant cognitive development: Social support versus TAU

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.121 Infant cognitive development: Home visits versus TAU

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – ITT analysis




Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – Available case analysis




1.5.122 Infant cognitive development: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant verbal development Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.123 Infant emotional development: Social support versus TAU

Infant 'difficult' temperament Post-treatment (maternal-rated mean score at endpoint or first measurement) – Available case analysis




1.5.124 Infant emotional development: Home visits versus TAU


Infant externalising Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Infant externalising Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Infant internalising Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis




Infant internalising Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis




Infant social withdrawal Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis



Infant social withdrawal Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis



Infant social withdrawal Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.125 Infant emotional development: Mother-infant relationship interventions versus TAU/Enhanced TAU


Infant adaptive behaviour Post-treatment (treatment response at endpoint or first measurement) – ITT analysis




Infant adaptive behaviour Post-treatment (treatment response at endpoint or first measurement) – Available case analysis




Infant adaptive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant externalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant internalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant dysregulation Post-treatment (mean score at endpoint or first measurement) – Available case analysis




Infant self-esteem Post-treatment (mean score at endpoint or first measurement) – Available case analysis



Infant externalising Very long Follow-up (mean score at >104 week follow-up) – Available case analysis




Infant internalising Very long Follow-up (mean score at >104 week follow-up) – Available case analysis




1.5.126 Infant emotional development: Infant sleep training (controlled crying) versus TAU

Infant externalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis



Infant internalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis



1.5.127 Prevention of neglect or abuse of the infant: Listening visits versus TAU


Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – ITT analysis



Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – Available case analysis



Child injury Long follow-up (Injury requiring medical attention at >24 week follow-up) – ITT analysis




Child injury Long follow-up (Injury requiring medical attention at >24 week follow-up) – by intervention




1.5.128 Prevention of neglect or abuse of the infant: Home visits versus TAU


Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – ITT analysis




Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – Available case analysis




Ingestion of poison Post-treatment (incidence during trial measured at endpoint or first measurement) – Available case analysis




Child protective service reports (all types) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – ITT analysis




Child protective service reports (all types) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – Available case analysis




Child protective service reports (neglect) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – ITT analysis




Child protective service reports (neglect) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – Available case analysis




Maternal use of punishment Post-treatment (corporate/verbal punishment used anytime in past week measured at endpoint or first measurement) – ITT analysis



Maternal use of punishment Post-treatment (corporate/verbal punishment used anytime in past week measured at endpoint or first measurement) – Available case analysis




Potential for child abuse Post-treatment (mean score at endpoint or first measurement) – Available case analysis




1.5.129 Optimal infant care: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Immunisation Post-treatment (complete immunisation at endpoint or first measurement) – ITT analysis




Immunisation Post-treatment (complete immunisation at endpoint or first measurement) – Available case analysis




1.6 PHARMACOLOGICAL INTERVENTIONS: PREVENTION (NO RISK FACTORS)

1.6.1 Depression: Omega-3 versus placebo


Depression mean symptoms - Post-treatment - score at endpoint or first measurement (no risk populations)




Depression mean symptoms - Short follow-up - score at long-term (60 week) follow-up (no risk populations)



Depression symptomology - Post-treatment - above threshold at endpoint or first measurement (no risk populations)



Depression symptomology - Post-treatment - above threshold at intermediate (24 week) follow-up (no risk populations)




Depression diagnosis – Post-treatment – current depression, new or existing during study period (no risk populations)




1.6.2 Depression: Selenium versus placebo

Depression mean scores – Post-treatment – score at endpoint or first measurement (no risk populations)



1.6.3 Depression: Calcium versus placebo


Depression mean scores – Post-treatment – score at short-term (9-16 weeks) follow-up (no risk factors)



Depression symptomology – Post-treatment – score at endpoint or first measurement (no risk populations)




Depression symptomology – Post-treatment – above threshold at short-term (9-16 weeks) follow-up (no risk populations)




1.6.4 Compliance: Selenium versus placebo

Compliance – Post-treatment – serum selenium concentrations at endpoint or first measurement (no risk populations)




1.6.5 Quality of life: Calcium versus placebo

Quality of life – Post-treatment – positive life events at first measurement (no risk populations)




Quality of life – Post-treatment – negative life events at first measurement (no risk populations)




1.6.6 Infant outcomes: Omega-3 versus placebo


Infant outcomes – Post-treatment – mean scores on the Bayley scales of Infant Development at long-term (78 weeks) follow – up (no risk populations)



Infant outcomes – Post-treatment – delayed cognitive performance at long term (78 weeks) follow-up (no risk populations)




Infant outcomes – Post-treatment – delayed language performance at long term (78 weeks) follow-up (no risk populations)




1.6.7 Leaving the study early: Omega-3 versus placebo

Leaving the study early – Post-treatment – end of the intervention (no risk populations)




1.6.8 Adverse events/ Service utilisation: Omega-3 versus placebo


Maternal hospitalisation for serious adverse events – Post-treatment – end of the intervention or first measurement (no risk populations)



Infant admission to neonatal intensive care hospitalisation for serious adverse events – Post-treatment – end of the intervention or first measurement (no risk populations)




Major congenital abnormality of the infant – Post-treatment – long-term (78 weeks) follow-up (no risk populations)




1.7 PHARMACOLOGICAL INTERVENTIONS (RISK FACTORS)

1.7.1 Depression: Thyroxine versus placebo


Depression symptomology – Post-treatment – above threshold at endpoint or first measurement (risk populations)



Depression diagnosis – Post treatment – major depression (definite and probable cases) at endpoint or first measurement (risk populations)




Depression diagnosis – Post treatment – any depression diagnosis at endpoint or first measurement (risk populations)




1.7.2 Depression: Norethisterone versus placebo

Depression mean scores – Post treatment – at endpoint or first measurement (risk populations)




Depression mean scores – Post treatment – at short-term follow-up (risk populations)



Depression symptomology - Post treatment - at endpoint or first measurement (risk populations)




Depression symptomology - Post treatment - above depression threshold at short-term (9-16 week) follow-up (risk populations)




1.7.3 Compliance: Thyroxine versus placebo

Compliance - Post-treatment - numbers not compliant at endpoint or first measurement (risk populations)




1.7.4 Mother-Infant interaction: Norethisterone versus placebo

Breastfeeding - Post-treatment - exclusive or partial breastfeeding at endpoint or first measurement (risk populations)




Breastfeeding – Post-treatment – exclusive or partial breastfeeding at short term (13 weeks) follow-up (risk populations)




1.7.5 Leaving the study early: Norethisterone versus placebo

Leaving the study early – Post-treatment – end of the intervention (risk populations)




Leaving the study early – Post-treatment short-term (17-19 weeks) follow-up (risk populations)




1.7.6 Adverse events: Norethisterone versus placebo


Vaginal bleeding – Post treatment – number of days at endpoint or first measurement (risk populations)




Vaginal bleeding – Post treatment – number of days at short-term follow-up (risk populations)



Troublesome bleeding – Post treatment – number at endpoint or first measurement (risk populations)




Sexual interest – Post treatment – no return of sexual interest at endpoint or first measurement (risk populations)



1.8 PHARMACOLOGICAL INTERVENTIONS: PREVENTION (PROPHYLAXIS)


1.8.1 Depression: SSRI (Sertraline) versus placebo

Recurrence of depression – Post-treatment – number at endpoint or first measurement (prophylaxis)




1.8.2 Depression: TCA (Nortriptyline) versus placebo

Recurrence of depression – Post-treatment – number at endpoint or first measurement (prophylaxis)



Recurrence of depression – Post-treatment – number at long-term (25-103 weeks) follow-up (prophylaxis)




1.8.3 Adverse events: SSRI (Sertraline) versus placebo

Dizziness - Post-treatment - number at endpoint or first measurement (prophylaxis)




Drowsiness - Post-treatment - number at endpoint or first measurement (prophylaxis)



1.8.4 Adverse events: TCA (Nortriptyline) versus placebo

Discontinuation due to adverse events - Post treatment - number at endpoint or first measurement (prophylaxis)




Constipation - Post treatment - number at endpoint or first measurement (prophylaxis)




1.8.5 Leaving the study early: SSRI (Sertraline) versus placebo

Leaving the study early for any reason except recurrence – Post-treatment – number at endpoint (prophylaxis)



1.8.6 Leaving the study early: TCA (Nortriptyline) versus placebo


Leaving the study early for any reason except recurrence – Post-treatment – number at endpoint (prophylaxis)




1.9 PHARMACOLOGICAL INTERVENTIONS: TREATMENT

1.9.1 Non-Response: Omega-3 versus Placebo

Non-response – Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)



Non-remission - Post-treatment - number at endpoint or first measurement - Available case analysis (treatment)




Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




1.9.2 Non-response to treatment: SSRIs (sertraline/paroxetine) versus placebo


Non-response – Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




Non-response – Post-treatment – number at endpoint or first measurement – ITT analysis (treatment)



Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)



Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)



1.9.3 Non-response to treatment: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions

Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




1.9.4 Non-response to treatment: SSRIs versus TCA


Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




Non-response - Post-treatment - number at endpoint or first measurement - Available case analysis (treatment)




Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




Non-remission – Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)



Non-response – Post-treatment – number at intermediate follow-up (20-24 weeks – end of continuation phase) – ITT analysis (treatment)




Non-response – Post-treatment – number at intermediate follow-up (20-24 weeks – end of continuation phase) – Available case analysis (treatment)




1.9.5 Depression: SSRIs versus Placebo

Mean depression scores Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




1.9.6 Depression: SSRIs versus TCA

Mean depression scores Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




Mean depression scores – Post-treatment – number at intermediate follow-up – Available case analysis (treatment)




1.9.7 Depression: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions

Mean depression scores – Post-treatment – score at endpoint or first measurement – Available case analysis (treatment)




Mean depression scores Post-treatment – score at endpoint or first measurement – ITT analysis (treatment)




1.9.8 Depression: Antidepressants versus general supportive care


Depression symptomology Post-treatment-above depression threshold at endpoint or first measurement – Available case analysis (treatment)



Depression symptomology Post-treatment-above depression threshold at endpoint or first measurement – ITT analysis (treatment)




Mean depression scores – Post-treatment-above depression threshold at endpoint or first measurement – Available case analysis (treatment)




1.9.9 Depression: Omega-3 versus Placebo

Mean depression scores Post-treatment – score at endpoint or first measurement – ITT analysis (treatment)




1.9.10 Depression: Hormones (transdermal oestrogen) versus placebo

Depression symptomology – Post-treatment – score at endpoint or first measurement – ITT analysis (treatment)




Depression symptomology – Post-treatment – score at endpoint or first measurement – Available case analysis (treatment)




1.9.11 General mental health: SSRIs versus TCA


Mean global assessment of functioning – Post-treatment – score at endpoint or first measurement – Available case analysis (treatment)




Social problems Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




Mean global assessment of functioning – Post-treatment – score at Intermediate follow-up – Available case analysis (treatment)



Social problems Post-treatment – number at Intermediate follow-up – Available case analysis (treatment)




Global severity and improvement – Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)




1.9.12 General mental health: SSRIs combined with psychosocial interventions versus placebo combined with psychosocial interventions


Global severity – Post-treatment – mean scores at endpoint or first measurement – ITT analysis (treatment)




Global Improvement – Post-treatment – mean scores at endpoint or first measurement – ITT analysis (treatment)



Distress – Post-treatment – mean scores at endpoint or first measurement – Available case analysis (treatment)




Distress – Post-treatment – mean scores at endpoint or first measurement – ITT analysis (treatment)




1.9.13 General mental health: SSRIs compared with placebo

Global severity and improvement – Post-treatment – mean scores at endpoint or first measurement – available case analysis (treatment)




1.9.14 Service utilisation: SSRIs combined with psychosocial interventions compared with Placebo combined with psychosocial interventions

Lorazepam use - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)



1.9.15 Service Utilisation: SSRIs compared with Placebo

Benzodiazepine use - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)




1.9.16 Leaving the Study early: SSRIs combined with psychological interventions compared with Placebo combined with psychological interventions

Leaving the study early due to adverse events - Post-treatment number at endpoint or first measurement - Available case analysis (treatment)




Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)




1.9.17 Leaving the Study early: SSRIs compared with Placebo

Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)



1.9.18 Leaving the Study early: SSRIs compared with TCAs

Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)




1.9.19 Leaving the Study early: Hormones versus placebo

Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)




1.9.20 Leaving the Study early: Omega-3 versus Placebo

Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)




1.9.21 Adverse events: SSRI combined with psychosocial interventions compared with Placebo compared with psychosocial interventions

Major adverse events (hypomanic switch) – Post-treatment number at endpoint or first measurement – ITT analysis (treatment)




Side events (hypomanic switch) – Post-treatment mean score at endpoint or first measurement – ITT analysis (treatment)




1.9.22 Adverse events: omega-3 versus placebo


Possible hypomanic side effects – Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)



Suicide – Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)




Any mild/transient side effects – Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)




1.9.23 Adverse events: SSRIs versus placebo


Decreased appetite - Post-treatment - number at endpoint or first measurement - Available case analysis




Diarrhoea - Post-treatment - number at endpoint or first measurement - Available case analysis




Dizziness - Post-treatment - number at endpoint or first measurement - Available case analysis




Headache - Post-treatment - number at endpoint or first measurement - Available case analysis




Nausea – Post-treatment – number at endpoint or first measurement – Available case analysis



Somnolence – Post-treatment – number at endpoint or first measurement – Available case analysis




Dry mouth – Post-treatment – number at endpoint or first measurement – Available case analysis



1.9.24 Compliance: SSRIs versus Placebo


Non – compliance – Post-treatment – number at endpoint or first measurement – Available case analysis




1.10 HARMS FOR ASSOCIATED WITH SPECIFIC DRUGS

1.10.1 Antidepressants: Teratogenic harms


SSRIs – Teratogenic harms – Congenital malformations-cohort design




SSRIs – Teratogenic harms – Congenital malformations-case control design




TCAs – Teratogenic harms – Congenital malformations-cohort design




Paroxetine – Teratogenic harms – Congenital malformations-cohort design




Citalopram – Teratogenic harms – Congenital malformations-cohort design




Fluoxetine – Teratogenic harms – Congenital malformations-cohort design




Sertraline – Teratogenic harms – Congenital malformations-cohort design




Fluvoxamine – Teratogenic harms – Congenital malformations-cohort design




Escitalopram – Teratogenic harms – Congenital malformations-cohort design




Venlafaxine - Teratogenic harms - Congenital malformations-cohort design




Any antidepressant - Teratogenic harms - Major congenital malformations-case-cohort design




SSRIs - Teratogenic harms - Major congenital malformations-cohort design




Paroxetine – Teratogenic harms – Major congenital malformations-cohort design




Citalopram – Teratogenic harms – Major congenital malformations-cohort design




Fluoxetine – Teratogenic harms – Major congenital malformations-cohort design




Sertraline – Teratogenic harms – Major congenital malformations-cohort design




Fluvoxamine – Teratogenic harms – Major congenital malformations-cohort design




Escitalopram – Teratogenic harms – Major congenital malformations-cohort design




Venlafaxine – Teratogenic harms – Major congenital malformations-cohort design




SSRIs – Teratogenic harms – Cardiac malformations-cohort design




TCAs – Teratogenic harms – Cardiac malformations-cohort design




Paroxetine – Teratogenic harms – Cardiac malformations-cohort design




Paroxetine – Teratogenic harms – Cardiac malformations-case-cohort design




Citalopram – Teratogenic harms – Cardiac malformations-cohort design




Fluoxetine – Teratogenic harms – Cardiac malformations-cohort design




Sertraline – Teratogenic harms – Cardiac malformations-cohort design




Fluvoxamine – Teratogenic harms – Cardiac malformations-cohort design




Escitalopram – Teratogenic harms – Cardiac malformations-cohort design




Venlafaxine – Teratogenic harms – Cardiac malformations-cohort design




SSRIs – Teratogenic harms – ASD and/or VSD-cohort design




Paroxetine – Teratogenic harms – ASD and/or VSD-cohort design




Citalopram – Teratogenic harms – ASD and/or VSD-cohort design




Fluoxetine – Teratogenic harms – ASD and/or VSD-cohort design




Sertraline – Teratogenic harms – ASD and/or VSD-cohort design




Fluvoxamine – Teratogenic harms – ASD and/or VSD-cohort design




Escitalopram – Teratogenic harms – ASD and/or VSD-cohort design




SSRIs – Teratogenic harms – ASD-cohort design




Paroxetine – Teratogenic harms – ASD-cohort design




Citalopram – Teratogenic harms – ASD-cohort design




Fluoxetine – Teratogenic harms – ASD-cohort design




Sertraline – Teratogenic harms – ASD-cohort design




Fluvoxamine – Teratogenic harms – ASD-cohort design




Escitalopram – Teratogenic harms – ASD-cohort design




SSRIs – Teratogenic harms – VSD-cohort design




Paroxetine – Teratogenic harms – VSD-cohort design




Citalopram – Teratogenic harms – VSD-cohort design




Fluoxetine – Teratogenic harms – VSD-cohort design




Sertraline – Teratogenic harms – VSD-cohort design



Fluvoxamine – Teratogenic harms – VSD-cohort design




Escitalopram – Teratogenic harms – VSD-cohort design




1.10.2 Antidepressants: Neonatal and obstetric complications


SSRIs – Neonatal and obstetric complications – Miscarriage-cohort design




SSRIs – Neonatal and obstetric complications – Pre-term delivery-cohort design




Any antidepressant – Neonatal and obstetric complications – PNAS-cohort design




SSRIs – PPHT – Neonatal and obstetric complications – Cohort design



Any antidepressant – Respiratory distress – Neonatal and obstetric complications – Cohort design




Any antidepressant – Tremors – Neonatal and obstetric complications – Cohort design




1.10.3 Antipsychotics: Teratogenic harms

Any antipsychotic - Teratogenic harms-Congenital malformations - Cohort design




Any antipsychotic - Teratogenic harms-Major congenital malformations - Cohort design




1.10.4 Antipsychotics: Neonatal and Obstetric Complications


Any antipsychotic – Neonatal and obstetric complications-Gestational diabetes – Cohort design




Any antipsychotic – Neonatal and obstetric complications-Small for gestational age – Cohort design




Any antipsychotic – Neonatal and obstetric complications-Large for gestational age – Cohort design




Any antipsychotic – Neonatal and obstetric complications-LBW (<2500g) – Cohort design




Any antipsychotic – Neonatal and obstetric complications-birth-weight - Cohort design




Any antipsychotic – Neonatal and obstetric complications-birth-weight - Case-control design




Any antipsychotic – Neonatal and obstetric complications-preterm delivery – Cohort design




Any antipsychotic – Neonatal and obstetric complications-Miscarriage Cohort design




Any antipsychotic – Neonatal and obstetric complications-still birth – Cohort design



Any antipsychotic – Neonatal and obstetric complications-Caesarean delivery – Cohort design




Any antipsychotic – Neonatal and obstetric complications-Gestational age at delivery – Cohort design




1.10.5 Antipsychotics: Neurodevelopmental outcomes


Any antipsychotic – Neurodevelopmental outcome – Mean score on the Infant Neurological Battery (at 6 months) – cohort design



Any antipsychotic – Neurodevelopmental outcomes-Delayed development – Bayley scales of infant development <85 – Cohort design




Any antipsychotic – Neurodevelopmental outcomes-Score on Bayley scales of infant development – Cohort design




1.10.6 Anticonvulsants: Teratogenic harms


Carbamazepine – Teratogenic harms – Major congenital malformations-cohort design




Lamotrigine – Teratogenic harms – Major congenital malformations-cohort design




Valproate – Teratogenic harms – Major congenital malformations-cohort design




Valproate – Teratogenic harms – Major congenital malformations – case control design




Carbamazepine – Teratogenic harms – Congenital malformations-cohort design




Valproate – Teratogenic harms – Congenital malformations-cohort design




Anticonvulsants – Teratogenic harms – neural tube defects-cohort design




Carbamazepine – Teratogenic harms – cleft lip/palate – cohort design



Lamotrigine – Teratogenic harms – cleft lip/palate – cohort design




Valproate - Teratogenic harms - cleft lip/palate - cohort design




1.10.7 Anticonvulsants: Neonatal and Obstetric harms


Carbamazepine - Neonatal and obstetric complications - admission to neonatal care - cohort design




Lamotrigine - Neonatal and obstetric complications - admission to neonatal care - cohort design




Valproate - Neonatal and obstetric complications - admission to neonatal care - cohort design




Carbamazepine – Neonatal and obstetric complications – stillbirth/perinatal death – cohort design




Lamotrigine – Neonatal and obstetric complications – stillbirth/perinatal death – cohort design




Valproate – Neonatal and obstetric complications – stillbirth/perinatal death – cohort design




Carbamazepine – Neonatal and obstetric complications – preterm birth – cohort design




Lamotrigine - Neonatal and obstetric complications - preterm birth - cohort design




Valproate - Neonatal and obstetric complications - preterm birth - cohort design



Carbamazepine - Neonatal and obstetric complications - birth weight - cohort design




Valproate - Neonatal and obstetric complications - birth weight - cohort design




1.10.8 Anticonvulsants: Neurodevelopmental outcomes


Carbamazepine – Neurodevelopmental outcomes – Full scale IQ – cohort design




Lamotrigine – Neurodevelopmental outcomes – Full scale IQ – cohort design




Valproate – Neurodevelopmental outcomes – Full scale IQ – cohort design




Carbamazepine – Neurodevelopmental outcomes – Verbal IQ – cohort design




Lamotrigine – Neurodevelopmental outcomes – Verbal IQ – cohort design




Valproate – Neurodevelopmental outcomes – Verbal IQ – cohort design



Carbamazepine – Neurodevelopmental outcomes – Performance IQ – cohort design




Lamotrigine – Neurodevelopmental outcomes – Performance IQ – cohort design




Valproate – Neurodevelopmental outcomes – Performance IQ – cohort design




Carbamazepine – Neurodevelopmental outcomes – Autism checklist score – cohort design




Lamotrigine – Neurodevelopmental outcomes – Autism checklist score – cohort design




Valproate – Neurodevelopmental outcomes – Autism checklist score – cohort design




Carbamazepine – Neurodevelopmental outcomes – Autism spectrum disorder – cohort design



Lamotrigine – Neurodevelopmental outcomes – Autism spectrum disorder – cohort design




Valproate – Neurodevelopmental outcomes – Autism spectrum disorder – cohort design




1.10.9 Lithium: Teratogenic harms


Lithium – Teratogenic harms – Congenital malformations – cohort design




Lithium – Teratogenic harms – Congenital malformations – case-control design



Lithium – Teratogenic harms – Heart defects – cohort design




Lithium – Teratogenic harms – Ebstein's anomaly – cohort design




1.10.10 Benzodiazepines: Teratogenic harms


Benzodiazepines – Teratogenic harms – congenital malformations – cohort design




Benzodiazepines – Teratogenic harms – congenital malformations – case-control design




Benzodiazepines – Teratogenic harms – major congenital malformations – cohort design




Benzodiazepines – Teratogenic harms – major congenital malformations – case-control design




Benzodiazepines – Teratogenic harms – cleft lip/palate – cohort design




Benzodiazepines – Teratogenic harms – cleft lip/palate – case-control design




Benzodiazepines – Teratogenic harms – cardiac abnormalities – cohort design



Benzodiazepines – Teratogenic harms – septal heart defects – cohort design




Benzodiazepines – Teratogenic harms – atrioventricular defects – cohort design




1.10.11 Benzodiazepines: Neonatal and Obstetric complications


Benzodiazepines – Neonatal and obstetric complications – gestational age at delivery – cohort design




Benzodiazepines – Neonatal and obstetric complications – birth weight – cohort design




Benzodiazepines – Neonatal and obstetric complications – caesarean delivery – cohort design




Benzodiazepines – Neonatal and obstetric complications – miscarriage – cohort design



Benzodiazepines – Neonatal and obstetric complications – instrumental delivery – cohort design




Benzodiazepines – Neonatal and obstetric complications – respiratory disorder – cohort design



1.10.12 Stimulants (methylphenidate): Teratogenic harms

Methylphenidate – Teratogenic harms – Major congenital malformations – cohort design




Methylphenidate – Teratogenic harms – Cardiac malformations – cohort design



1.11 PHYSICAL INTERVENTIONS: PREVENTION

1.11.1 Depression: Physical activity versus treatment as usual

Depression scores – Post-treatment – mean score at endpoint or first measurement – Available case analysis (no risk factors)




Depression symptomology – Post-treatment – number at short term follow-up – Available case analysis (no risk factors)




1.11.2 Depression: Physical activity combined with psychoeducation versus psychoeducation alone

Depression symptomology – Post-treatment – number at short term follow-up – ITT analysis (no risk factors)




Depression symptomology – Post-treatment – number at short term follow-up – ITT analysis (no risk factors)




1.11.3 Acupuncture versus placebo

Anxiety mean scores – Post-treatment – Available case analysis (identified risk factors)




Anxiety mean cortisol level – Post-treatment – Available case analysis (identified risk factors)



1.12 PHYSICAL INTERVENTIONS: TREATMENT


1.12.1 Response: Acupuncture versus massage

Non-response to treatment – Post-treatment – number at short term follow-up – (treatment)




1.12.2 Response: Depression specific acupuncture versus non-specific acupuncture

Non-response to treatment – Post-treatment – at endpoint or first measurement – (treatment)




1.12.3 Response: Bright light therapy versus placebo

Non-response – Post-treatment – at endpoint or first measurement – (treatment)




Non-remission – Post-treatment – at endpoint or first measurement – (treatment)




1.12.4 Depression: Physical activity versus treatment as usual

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement/Intermediate follow-up – (treatment) – Available case analysis




1.12.5 Depression: Physical activity versus mutual support

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment) – Available case analysis




Depression symptoms – Mean depression scores Post-treatment – short-term follow-up – (treatment) – Available case analysis




1.12.6 Depression: Acupuncture versus massage


Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment) – Available case analysis



Depression symptoms – Mean depression scores Post-treatment – short-term follow-up – (treatment) – Available case analysis




Depression diagnosis – Above depression threshold – Post-treatment – short-term follow-up – (treatment) – Available case analysis




1.12.7 Depression: Depression-specific acupuncture versus non-depression specific acupuncture


Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)




Depression symptoms – Mean depression scores Post-treatment – at short-term follow-up – (treatment)



Depression diagnosis – Above depression threshold – Post-treatment-at endpoint or first measurement – (treatment)




Depression diagnosis – Above depression threshold – Post-treatment – short-term follow-up – (treatment)




1.12.8 Depression: Electroacupuncture versus non-invasive sham acupuncture

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)




1.12.9 Depression: Massage combined with support versus support

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)




1.12.10 Depression: Massage versus support

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)




Depression symptoms – Mean depression scores Post-treatment – at long-term follow-up – (treatment)




1.12.11 Depression: Bright light therapy versus placebo

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)




1.12.12 Anxiety: Physical activity versus treatment as usual

Anxiety symptoms – Mean anxiety scores Post-treatment – at endpoint or first measurement – Available case analysis (treatment)



1.12.13 Anxiety: Electroacupuncture versus non-invasive sham acupuncture

Anxiety symptoms – Mean anxiety scores Post-treatment – at endpoint or first measurement – (treatment)



1.12.14 General mental health outcomes: Physical activity versus treatment as usual

Sleep disturbance symptoms – Mean scores – Post-treatment – Available case analysis (treatment)

